Search

Your search keyword '"Vescovi, Angelo L."' showing total 112 results

Search Constraints

Start Over You searched for: Author "Vescovi, Angelo L." Remove constraint Author: "Vescovi, Angelo L." Database Unpaywall Remove constraint Database: Unpaywall
112 results on '"Vescovi, Angelo L."'

Search Results

1. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis

2. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies

4. Supplementary Figures from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

5. Data from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

6. Figure S5 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

7. Figure S3 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

8. Figure S5 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

10. Data from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

11. Figure S3 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

12. Figure S4 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

13. Figure S2 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

14. Supplementary Tables from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

15. Table S1 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

16. Supplementary Data from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

17. Figure S6 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

18. Supplementary Procedures from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

19. Data from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

20. Figure S1 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

21. Supplementary Figures from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

22. Figure S6 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

23. Figure S1 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

24. Data from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

26. Supplementary Tables from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

27. Figure S4 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

28. Table S1 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

29. Supplementary Procedures from Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells

30. Figure S2 from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

31. Supplementary Data from Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

33. Supplementary Methods, Figures 1-6 from Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells

34. Data from Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells

35. Data from Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors

36. Supplementary Figures 1-5, Table 1, Methods and Materials from Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors

37. Supplementary Figures 1-5, Table 1, Methods and Materials from Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors

38. Data from Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells

39. Supplementary Methods, Figures 1-6 from Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells

41. Growth factor independence underpins a paroxysmal, aggressive Wnt5aHigh/EphA2Low phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy

45. BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies

47. The adult human subventricular zone: partial ependymal coverage and proliferative capacity of cerebrospinal fluid

48. Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies

49. AQP4 Aggregation State Is a Determinant for Glioma Cell Fate

50. Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma

Catalog

Books, media, physical & digital resources